Collects real-world data on newer systemic treatments for atopic dermatitis
Records daily practice use and safety of biologics and JAK inhibitors in atopic dermatitis patients.
Plain-language title generated from the registry record
Registry title: BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
Key facts
- Where
- Amersfoort, Capelle aan den IJssel, Delft, Eindhoven, Groningen, Haarlem, Leeuwarden, Maastricht, Nijmegen, The Hague, Utrecht, and Zwolle, NetherlandsSee the 14 sites
Where in Netherlands
- Meander Medisch CentrumAmersfoort, NetherlandsTaking people
- IJsselland ZiekenhuisCapelle aan den IJssel, NetherlandsTaking people
- Reinier de Graaf ZiekenhuisDelft, NetherlandsTaking people
- Catharina ZiekenhuisEindhoven, NetherlandsTaking people
- University Medical Center GroningenGroningen, NetherlandsTaking people
- Spaarne GasthuisHaarlem, NetherlandsTaking people
- Medisch Centrum LeeuwardenLeeuwarden, NetherlandsTaking people
- Maastricht Univeristy Medical CenterMaastricht, NetherlandsTaking people
- Radboud University Medical CenterNijmegen, NetherlandsTaking people
- Haga ZiekenhuisThe Hague, NetherlandsTaking people
- DiakonessenhuisUtrecht, NetherlandsTaking people
- St Antonius ZiekenhuisUtrecht, NetherlandsTaking people
- University Medical Center UtrechtUtrecht, NetherlandsTaking people
- Isala Dermatologisch CentrumZwolle, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UMC Utrecht
- Trial code
- NCT03549416
- Record updated
- 28 March 2025
- Original description
The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and effect on other atopic comorbidities in a multicenter setting. The registry already consists of several additional modules concerning atopic comorbidities, like food allergy and asthma, and a module for conjunctivitis during biologic treatment.Read full original descriptionShow less
BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Diseases in Daily Practice
The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and effect on other atopic comorbidities in a multicenter setting. The registry already consists of several additional modules concerning atopic comorbidities, like food allergy and asthma, and a module for conjunctivitis during biologic treatment.
Inclusion: All adult and paediatric patients treated with new systemic treatments for AD will be asked for participation in the BioDay Registry.
Exclusion: Patients are not eligible for enrolment in case of presumed inability to answer questionnaires or not willing to answer questionnaires and will be excluded.